Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 4/20 | 0.69 |
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.68 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.68 |
| ▸ | CACNB1 | Q02641 | 4/20 | 0.68 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.59 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.59 |
| ▸ | TACR1 | P25103 | 3/20 | 0.58 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4157504 | 1.00 | SLC6A9 (0.69) | SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL29379324 | 1.00 | SLC6A9 (0.69) | SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL4139313 | 1.00 | SLC6A9 (0.69) | SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL4157348 | 0.97 | SLC6A9 (0.65) | SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C | |
| Hydrochloric Acid SCHEMBL4155569 | 0.96 | SLC6A9 (0.64) | SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL4140436 | 0.95 | SLC6A9 (0.64) | SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL4155492 | 0.95 | SLC6A9 (0.64) | SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL26840795 | 0.91 | CACNA2D1 (0.65) | SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL4143623 | 0.89 | CACNA2D1 (0.66) | SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL8224256 | 0.88 | CACNA2D1 (0.61) | SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735383-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2014-05-27 | — | — | US | claimed |
| EP-2041088-B1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC (US) | 2014-01-08 | — | — | EP | claimed |
| CN-101479243-B | Glycine transporter-1 inhibitors | AMGEN INC | 2013-01-02 | — | — | CN | claimed |
| US-20120195985-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2012-08-02 | — | — | US | claimed |
| US-20090227595-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | HITCHCOCK STEPHEN | 2009-09-10 | — | — | US | claimed |
| CN-101479243-A | Glycine transporter-1 inhibitors | AMGEN INC (US) | 2009-07-08 | — | — | CN | claimed |
| US-7538114-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2009-05-26 | — | — | US | claimed |
| EP-2041088-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | Amgen Inc. (US) | 2009-04-01 | — | — | EP | claimed |
| WO-2008002583-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2008-01-03 | — | — | WO | claimed |
| US-20080004289-A1 | Glycine transporter-1 inhibitors | AMGEN INC. | 2008-01-03 | — | — | US | claimed |
| US-20240052418-A1 | METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-02-15 | — | — | US | disclosed |
| WO-2023219548-A1 | SELECTIVE DOPAMINE INCREASE | SOBRERA PHARMA AB (SE) | 2023-11-16 | — | — | WO | disclosed |
| US-11813257-B2 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | DISC MEDICINE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814681-B2 | Method for predicting a subjects response to SLC modulator therapy | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-14 | — | — | US | disclosed |
| US-20220313139-A1 | APPARATUSES AND METHODS FOR IDENTIFICATION AND TREATMENT OF PATIENTS RESPONSIVE TO ANTIPSYCHOTIC AGENT THERAPY | SIEKMEIER PETER J (US) | 2022-10-06 | — | — | US | disclosed |
| EP-2041088-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | Amgen Inc. (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008002583-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004289-A1 | Glycine transporter-1 inhibitors | AMGEN INC. | 2008-01-03 | — | — | US | disclosed |
| US-20080004289-A1 | Glycine transporter-1 inhibitors | AMGEN INC. | 2008-01-03 | — | — | US | disclosed |
| US-20080004289-A1 | Glycine transporter-1 inhibitors | AMGEN INC. | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227595-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | SLC18A2, SLC7A11, SLC6A5 | SLC6A9 8/4885CACNA2D1 3216/4885CACNA1B 2467/4885 |
| US-20120195985-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | SLC18A2, SLC6A5, SLC1A2 | SLC6A9 6/4885CACNA2D1 3030/4885CACNA1B 1928/4885 |
| US-20080004289-A1 | Glycine transporter-1 inhibitors | SLC18A2, SLC7A11, SLC6A5 | SLC6A9 8/4885CACNA2D1 3216/4885CACNA1B 2467/4885 |
| US-11813257-B2 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | GFPT1, MPST, XPNPEP1 | SLC6A9 19/4885CACNA2D1 1580/4885CACNA1B 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.